A Review of the Giant Protein Titin in Clinical Molecular Diagnostics of Cardiomyopathies by Marta Gigli et al.
July 2016 | Volume 3 | Article 211
Review
published: 21 July 2016
doi: 10.3389/fcvm.2016.00021
Frontiers in Cardiovascular Medicine | www.frontiersin.org
Edited by: 
Georges Nemer, 
American University of Beirut, 
Lebanon
Reviewed by: 
Nazareno Paolocci, 
Johns Hopkins University, USA  
Jin O-Uchi, 
Brown University, USA
*Correspondence:
Luisa Mestroni  
luisa.mestroni@ucdenver.edu
†Marta Gigli and Rene L. Begay 
contributed equally.
Specialty section: 
This article was submitted 
to Cardiovascular Genetics 
and Systems Medicine, 
a section of the journal 
Frontiers in Cardiovascular Medicine
Received: 24 March 2016
Accepted: 27 June 2016
Published: 21 July 2016
Citation: 
Gigli M, Begay RL, Morea G, 
Graw SL, Sinagra G, Taylor MRG, 
Granzier H and Mestroni L 
(2016) A Review of the Giant 
Protein Titin in Clinical Molecular 
Diagnostics of Cardiomyopathies. 
Front. Cardiovasc. Med. 3:21. 
doi: 10.3389/fcvm.2016.00021
A Review of the Giant Protein 
Titin in Clinical Molecular 
Diagnostics of Cardiomyopathies
Marta Gigli1,2†, Rene L. Begay1†, Gaetano Morea1,2, Sharon L. Graw1, Gianfranco Sinagra2, 
Matthew R. G. Taylor1, Henk Granzier3 and Luisa Mestroni1*
1 Adult Medical Genetics Program, Cardiovascular Institute, University of Colorado Denver, Aurora, CO, USA, 2 Department of 
Cardiology, Hospital and University of Trieste, Trieste, Italy, 3 Molecular Cardiovascular Research Program, University of 
Arizona, Tucson, AZ, USA
Titin (TTN) is known as the largest sarcomeric protein that resides within the heart mus-
cle. Due to alternative splicing of TTN, the heart expresses two major isoforms (N2B 
and N2BA) that incorporate four distinct regions termed the Z-line, I-band, A-band, and 
M-line. Next-generation sequencing allows a large number of genes to be sequenced 
simultaneously and provides the opportunity to easily analyze giant genes such as TTN. 
Mutations in the TTN gene can cause cardiomyopathies, in particular dilated cardio-
myopathy (DCM). DCM is the most common form of cardiomyopathy, and it is charac-
terized by systolic dysfunction and dilation of the left ventricle. TTN truncating variants 
have been described as the most common cause of DCM, while the real impact of TTN 
missense variants in the pathogenesis of DCM is still unclear. In a recent population 
screening study, rare missense variants potentially pathogenic based on bioinformatic 
filtering represented only 12.6% of the several hundred rare TTN missense variants 
found, suggesting that missense variants are very common in TTN and are frequently 
benign. The aim of this review is to understand the clinical role of TTN mutations in DCM 
and in other cardiomyopathies. Whereas TTN truncations are common in DCM, there 
is evidence that TTN truncations are rare in the hypertrophic cardiomyopathy (HCM) 
phenotype. Furthermore, TTN mutations can also cause arrhythmogenic right ventricular 
cardiomyopathy (ARVC) with distinct clinical features and outcomes. Finally, the identifi-
cation of a rare TTN missense variant cosegregating with the restrictive cardiomyopathy 
(RCM) phenotype suggests that TTN is a novel disease-causing gene in this disease. 
Clinical diagnostic testing is currently able to analyze over 100 cardiomyopathy genes, 
including TTN; however, the size and presence of extensive genetic variation in TTN 
presents clinical challenges in determining significant disease-causing mutations. This 
review discusses the current knowledge of TTN genetic variations in cardiomyopathies 
and the impact of the diagnosis of TTN pathogenic mutations in the clinical setting.
Keywords: titin, TTN, familial cardiomyopathy, cardiovascular genetics, clinical genetics, heart failure, clinical 
diagnosis
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iNTRODUCTiON
Dilated cardiomyopathy (DCM) is defined by the presence of left 
ventricular (LV) or biventricular dilatation and systolic dysfunc-
tion in the absence of hypertension, valvular disease, or coronary 
artery disease sufficient to cause global systolic impairment 
(1). The prevalence of the disease is about 1:2,500, and DCM 
explains about half of the heart failure cases in the United States. 
About 35–40% of DCM cases are classified as “idiopathic” or 
“familial/genetic” cardiomyopathy (2). Other causes of the DCM 
phenotype are ischemic, congenital, valvular, inflammatory, or 
cardiotoxic heart disease. Finally, other rare cardiomyopathies, 
such as hypertrophic cardiomyopathy (HCM), arrhythmogenic 
right ventricular cardiomyopathy (ARVC), and restrictive cardio-
myopathy (RCM), have genetic causes.
In this setting, genetics can justify a significant proportion of 
DCM cases (up to 25%), so the disease can be classified into genetic 
and non-genetic forms (3). In DCM, the most common form of 
cardiomyopathy, more than 50 genes have been associated with 
the phenotype, usually with incomplete penetrance and variable 
expressivity, and frequently with familial transmission (2–4). 
Evidence suggests that familial DCM is inherited in an autosomal 
dominant pattern in about 90% of cases, but few cases follow an 
autosomal recessive, x-linked, or mitochondrial pattern of inher-
itance (5–7). Genes most frequently involved in the disease are 
encoding structural proteins of the sarcomere (titin and myosin 
heavy chain), cytoskeleton (desmin), nuclear membrane (lamin 
A/C), membrane proteins and ion channels (phospholamban 
and presenilin), protein of the dystrophin-glycoprotein complex 
(dystrophin and sarcoglycan), desmosomes (desmoplakin and 
desmoglein), mitochondrial proteins (frataxin), and extracellular 
matrix proteins (alpha-laminin) (8).
Titin (TTN) encodes the largest human protein, whose name 
stems from the word Titans, giants of Greek mythology. Among 
the genes involved in cardiomyopathies, TTN plays a central role 
because of its frequency and the key structural, mechanical, and 
regulatory role within the sarcomere in the striated muscle (9). The 
TTN gene consists of 364 exons, located on chromosome 2q31, 
that produces maximally a 4,200-kDa protein which is composed 
of ~38,000 amino acid residues. The size and complex structure 
of the TTN protein provides architectural support, maintaining 
the sarcomeric organization during contraction, and developing 
passive tension during muscle stretching. It also has a sensory and 
signaling role through the multiple TTN-binding proteins that are 
organized in signaling hot spots (10–12). The protein is organized 
in four structural and functional regions: the N-terminal Z-line 
(anchor to the sarcomeric Z-disk), the I-band (responsible for 
elastic properties), A-band regions (with a stabilizer role of the 
thick filament), and the C-terminal M-line extremity (overlap in 
antiparallel orientation with another C-terminal TTN molecule; 
modulation of TTN expression and turnover with the tyrosine 
kinase domain) (10).
Truncation mutations of TTN are the most frequent in DCM 
where 25% of cases are familial forms and 18% are sporadic forms 
of DCM (13). However, it remains to be confirmed that TTN 
truncating mutations are always pathogenic (3, 14). Interestingly, 
truncations in the A-band region of TTN accounts for up to 
25% of DCM cases (15). Furthermore, TTN is involved in the 
pathogenesis of other cardiomyopathies such as HCM and ARVC 
that is considered to be a genetic disease (30–50% of cases are 
familial), and RCM.
After the introduction of next-generation sequencing (NGS), 
the study of TTN gene mutations, previously difficult to analyze 
due to its size and complexity, has now allowed the identification 
of more than 60,000 TTN missense variants (reported in the 1000 
Genomes Project) (16, 17). The aim of this review is to discuss the 
challenges in diagnosing the correlation between TTN mutations 
and the different types of cardiomyopathy in the clinical setting.
MeCHANiSTiC STUDieS OF TTN
Titin is the largest human protein. Two TTN filaments with 
opposite polarity span each sarcomere, namely, the contractile 
unit in striated muscle cells. TTN is responsible for sarcomere 
passive stiffness generation (18). TTN is composed of a Z-disk 
at its N-terminus, whereas the remaining part of the molecule 
is composed of the elastic I-band region (consisting of tandem 
Ig segments of serially-linked Ig-like domains), the spring-like 
PEVK region (is composed of proline (P), glutamate (E), valine 
(V), and lysine (K)), three unique sequences of Novex1, 2, and 3, 
cardiac-specific N2B and N2A domains, a thick A-band region, 
and a M-band region embedding the C-terminus (Figures  1 
and 2) (19–21). The extensible I-band region gradually lengthens 
and develops passive tension when the sarcomere is stretched 
during diastole (15). The inextensible A-band binds myosin 
and myosin-binding protein C (MyBP-C), whereas the M-band 
contains a kinase that affects gene expression and cardiac 
remodeling (22).
The 364 exons of TTN undergo extensive alternative splicing 
to encode different isoforms. In cardiomyocytes, three different 
isoforms of titin are expressed: adult N2BA, adult N2B, and 
the fetal cardiac titin (FCT) isoforms. The I-band sequence 
defines the different proprieties of each isoform, whereas the 
Z-disk, A-band, and M-line regions are extremely conserved 
(22). The isoforms, N2BA and N2B are expressed 30–40 and 
60–70% respectively, within the TTN protein in healthy adult 
human heart. The ratio between these two isoforms is a major 
determinant of the cardiomyocyte stiffness (18). Due to the 
longer extensible I-band region, the N2BA titin isoform is 
more compliant than N2B titin (23–25). The compliant N2BA 
contains additional spring elements in the PEVK and tandem 
Ig regions and is therefore associated with low cardiomyocyte 
passive tension (25). The TTN-based passive tension is estab-
lished by the TTN expression ratio in the human heart. There 
is a strong relationship between the TTN-based passive tension 
and the size of the I-band region: the larger the elastic I-band 
region and the lower the passive tension (22). Variable isoform 
expression and TTN splicing have become of great importance 
in different cardiac diseases, including DCM, whereby the 
compliant N2BA isoform is upregulated and is associated with 
decreasing passive stiffness and increasing chamber  compliance 
(23, 24, 26, 27).
A recent study by Roberts et  al. suggested that the clinical 
significance of TTN truncating variants is largely predicated by 
FiGURe 1 | Domain structure of titin isoforms and binding sites of titin ligands. (A) N2B and N2BA titin isoforms represented in the cardiac half-sarcomere, (B) 
Domain structure of titin sequence, Q8WZ42-1, with ligand binding sites represented (from Linke and Hamdani, with permission) (60).
FiGURe 2 | Domain structure of titin isoforms. (A) The spring segment, 
(B) difference in the domain structure of different isoforms, and (C) the 
relationship of the passive tension with the sarcomere length in the different 
isoforms. FTC, fetal cardiac titin.
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the exon usage and variant location (the distance of the truncat-
ing variant from the protein N-terminus) (28). Furthermore, 
the authors compared TTN truncating variants among different 
isoforms and found TTN truncating variants altering both N2BA 
and N2B were overrepresented in DCM patients versus controls 
and more strongly associated with DCM as compared with the 
TTN truncations involving the N2BA isoform only. Conversely, 
the TTN truncations of the controls were composed of exons not 
incorporated into N2BA and N2B transcripts (28).
The TTN gene structure is organized to accommodate exten-
sive splicing events. Roberts et al. defined a percentage spliced 
in (PSI) score based on RNA sequencing data from end-stage 
DCM and donor heart in order to find the mean usage of each 
TTN exon (28). The PSI estimates the proportion of transcripts 
that incorporate a given exon. A high PSI was given to an exon 
constitutively expressed and present in all TTN isoforms, while a 
low PSI was usually present only in one isoform and had a lower 
expression. Moreover, exon symmetry was related to PSI: only 
3 exons among the 175 with PSI < 0.99 were asymmetric versus 
27% of those with PSI >  0.99. Interestingly, the authors found 
that more than 80% of all TTN exons were symmetric and that 
their exclusion would not alter the translational reading frame. 
For instance, in the I-band, the region with the lower PSI, 93% 
of alternately spliced exons were symmetric: a truncating vari-
ant in that region will fall in exons spliced out or not expressed 
in the majority of the transcripts and should not have such a 
4Gigli et al. Titin Review in Clinical Diagnosis
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deleterious effect. While the stiffness of TTN is defined primarily 
by the I-band segment sequence of each isoform, it is well known 
that the cardiac passive tension can be affected by multiple post- 
translational modifications of contractile and regulatory proteins 
(29). Few studies have discovered that protein kinase phospho-
rylation significantly alters the stiffness of N2B and PEVK spring 
elements (30, 31). The N2B spring element is phosphorylated by 
PKA and PKG with a reduction in passive tension (29, 32).
The mechanisms responsible for the changes in TTN isoform 
expression are still not completely understood; however, it has 
been shown that RNA-Binding Motif Protein 20 (RBM20), a 
RNA splicing factor, plays an important role in this process and a 
reduced expression of RBM20 can alter TTN splicing and isoform 
expression in human (33) and mice (34), leading to DCM.
Therefore, the TTN-based myocardial stiffness is determined 
by the TTN isoform composition and the phosphorylation state 
of TTN’s elastic I-band. Different kinases can modify the TTN 
elasticity in different ways; indeed, it is known that changes in 
post-translational modification (in particular hypophosphoryla-
tion) plays a role in the pathophysiology of heart disease (13).
TiTiN iN THe PATHOGeNeSiS  
OF DiLATeD CARDiOMYOPATHY
Dilated cardiomyopathy is a primary myocardial disease with 
variable natural history and clinical presentation affecting young 
individuals with a potential long life expectancy. A genetic etiology 
is demonstrated in ~30% of cases (35), and the giant muscle TTN 
protein has been recognized as the major human disease-causing 
gene for DCM (9). The advances in contemporary DNA sequenc-
ing and the introduction of NGS have allowed the screening of 
TTN in large cohorts of patients with DCM and in the past few 
years have been prolific in the description of new DCM-related 
TTN mutations. A comprehensive cohort study by Herman et al. 
(16) on 312 DCM patients reported TTN truncating mutations to 
be the cause of DCM in 25 and 18% of familial DCM and sporadic 
cases, respectively. TTN truncating mutations found in subjects 
with DCM were overrepresented in the A-band region and were 
absent from the Z-disk and M-band regions. Interestingly, TTN 
truncation variants were also present in up to 2% of the control 
population, but the control subjects were less enriched for the 
A-band region of TTN including the Z-band variants. A recent 
study by Pugh et al. (36) confirmed the presence of truncating 
variants in the general population (1.65%) and demonstrated that 
truncating variants located in the A-band are more common in 
patients with DCM compared with controls. The rate of TTN 
truncating variants found by Pugh et al., in the DCM cohort was 
~14%. In addition, a reduced frequency of variants in the I-band 
was identified in probands compared with controls, whereas no 
differences were detected in the Z and M bands.
The TTN gene has also been evaluated in the European 
Atlas study of 639 patients with sporadic or familial DCM by 
NGS. Mutations in TTN were identified in 19% of familial and 
11% of sporadic cases (37). Noteworthy, 44% of patients with 
a truncating TTN variant also presented an additional known 
disease-causing variant in at least one other gene involved in 
the pathogenesis of DCM; thus in these cases, the TTN variant 
may not be the only contributor leading to the pathogenesis 
of DCM (37).
A large study recently compared the burden of rare TTN 
variants across five cohorts of healthy volunteers, participants in 
the Framingham Heart Study, participants in the Jackson Heart 
Study, cohort of unselected ambulatory patients with DCM, 
and end-stage DCM cases. The authors confirmed that TTN 
truncations were not uniformly distributed within and between 
study groups, being more common in patients with DCM (22%), 
but with a rate in the healthy volunteers ranging between 1 and 
2.9% (28). The TTN truncation variants in the DCM cohort were 
located predominantly in the A-band, as already described in 
previous studies mentioned above (16, 36).
The role of TTN truncation mutations in the pathogenesis of 
DCM has been largely recognized. However, the high prevalence 
of missense variants and the potential modifier effects make it 
difficult to elucidate the effective role of TTN missense variants 
in DCM. Some of these variants are proposed to be pathogenic, 
but other variants are of unknown significance (VUS). In order to 
address this challenge, a recent multicenter study sequenced the 
TTN gene in a cohort of 147 DCM patients (38). In this cohort, 13 
TTN truncating variants had previously been reported (16), and 
348 missense variants were filtered by bioinformatic algorithms 
resulting in 44 out of 348 (involving 37 probands) classified as 
“severe” or likely pathogenic. Among the nine families with TTN 
variants classified as “severe,” five were considered false positives 
due to discordant cosegregation analysis among affected relatives, 
whereas four families had “severe” TTN variants that cosegregated 
with the DCM phenotype. The remaining 28 probands harbored 
“severe” variants that could not be assessed by cosegregation (pos-
sibly pathogenic). Furthermore, the outcome of TTN missense 
variants carriers did not differ significantly from the other DCM 
patients (Figure  3). Interestingly, the distribution of the likely 
and possibly TTN severe missense variants across TTN domains 
was again non-random and was overrepresented in the A-band 
region of TTN. Specifically, variants were overrepresented in 
the C-zone of the A-band, which consists of a super repeat of 
11 immunoglobulin-like domains and Fn-III domains shown to 
bind to MyBP-C and subfragment myosin-1, and is essential for 
the length dependency of force development and calcium sensi-
tivity (39). Therefore, although the real impact of TTN missense 
variants in the pathogenesis of DCM is still unclear, the clustering 
of variants in the A-band in DCM may suggest that some A-band 
missense variants may have a functional detrimental effect on 
contractility and should be further investigated.
TiTiN iN OTHeR FORMS OF 
CARDiOMYOPATHY
Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy is a common and inherited car-
diomyopathy with a prevalence of 1 in 500 (40). HCM presents as 
an unexplained LV hypertrophy, myocardial disarray, and fibrosis 
that translate in increased risk of life-threatening ventricular 
arrhythmias, sudden cardiac death, and an increased life-long 
risk of heart failure (41, 42). In the majority of cases, HCM has 
FiGURe 3 | Long-term survival curves in TTN variant carriers. 
Kaplan–Meier event-free survival for cardiovascular death (CVD) or heart 
transplantation (HTx) based on TTN variant categories: truncations (TRUNC); 
“likely” and “possibly” missense variants; non-carriers (NC), and “unlikely” 
with lack of cosegregation. TTN indicates titin gene (from Begay et al., with 
permission) (38).
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an autosomal dominant trait and mutations in at least 11 differ-
ent genes. These genes encode for sarcomeric proteins that are 
responsible for 50–65% of familial cases (9). While TTN trunca-
tion mutations are common in DCM, there is evidence that TTN 
truncations are rare in the HCM phenotype, with a frequency 
similar to control populations (16). Using high-throughout 
sequencing in 142 HCM probands, Lopes et  al. found 219 
TTN rare variants with 209 being novel missense variants (43). 
However, this cohort of individuals potentially had a sarcomeric 
gene mutation that likely caused HCM, and the actual pathogenic 
role of these TTN variants in unknown.
Restrictive Cardiomyopathy
Restrictive cardiomyopathy is a very rare form of cardiomyopathy, 
characterized by preserved biventricular systolic function and a 
restrictive physiology determining an impaired LV filling despite 
normal cavity size and frequently normal wall thickness. RCM can 
be secondary to idiopathic or system disease. It is believed that a 
significant proportion of RCM cases are genetically determined 
(42). The pattern of inheritance can be autosomal dominant, 
autosomal recessive, or x-linked (44). The overall prognosis of 
RCM is poor, usually resulting in progressive biventricular heart 
failure with a high mortality rate in the absence of heart trans-
plantation. Interestingly, RCM overlaps in clinical features with 
HCM (42). Recently, a study using linkage analysis that reported 
a TTN missense variant (TTN: c.22862A>G) cosegregating with 
RCM in six affected individuals of a family. The most common 
genes were excluded due to lack of complete cosegregation. 
Interestingly, some healthy individuals also harbored the TTN 
missense variant resulting in an incomplete penetrance (44). The 
identification of a rare missense variant in TTN cosegregating 
with the RCM disease phenotype suggests that TTN is a novel 
disease-causing gene for RCM.
Arrhythmogenic Right ventricular 
Cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy is considered 
to be a genetic disease (30–50% of cases) mainly with autosomal 
dominant pattern of inheritance (45). ARVC is characterized by 
fibrofatty replacement of the myocardium, predominantly of the 
right ventricle, although the left ventricle can also be involved. 
Typical symptoms include palpitations, cardiac syncope, and 
cardiac arrest due to ventricular arrhythmias. Heart failure may 
develop later in life as a result of this disease (46). One study 
by Taylor et  al. in which the investigators analyzed by direct 
sequencing of 312 exons of TTN (311 expressing TTN protein) 
found TTN mutations to be associated with the ARVC phenotype 
(47). Among seven different probands with an ARVC phenotype, 
eight TTN rare variants (two TTN variants present in one 
proband) were identified (47). In addition to this study, another 
investigation by Brun et  al. compared the clinical outcomes of 
ARVC patients with TTN mutations, desmosomal mutations, 
and patients with no identifiable mutation (non-carriers) (45). 
In this study, 13% of TTN rare variants were accounted for in 
their population of subjects. Among the 67 ARVC affected 
patients (39 ARVC families), 11 harbored rare TTN variants and 
8 desmosomal genes variants. The TTN carriers had increased 
supraventricular arrhythmias, and conduction disease compared 
with non-carriers (45), while desmosomal gene variant carriers 
had the worse prognosis. In conclusion, these studies suggest that 
TTN mutations can cause ARVC and TTN mutation carriers have 
distinct clinical features and outcomes.
TiTiN AS A GeNe MODiFieR
TTN variants are very frequent; of them, pathogenic mutations are 
relatively rare and most variants are probably benign. However, 
a portion of these variants could have a modifier gene effect. For 
instance, TTN has been proposed as a modifier gene in combina-
tion with the Lamin A/C (LMNA) gene (48, 49). A modifier gene 
is not the causal gene, but it may affect the phenotypic expression 
(50). In a study by Roncarati et al., the authors reported a TTN 
missense mutation modifying the DCM phenotype primarily 
caused by a LMNA mutation. The authors analyzed 41 Italian 
patients using whole exome sequencing (WES). Fourteen indi-
viduals harbored LMNA: c.656A>C mutation, and of those five 
also carried a novel TTN missense mutation (TTN: c.14563C>T) 
as well (48). LMNA gene mutations are known to be causative of a 
specific phenotype expression of DCM (51). According to Taylor 
et al., patients carrying a LMNA mutation show a poor prognosis 
and experience high event-rates compared with non-carriers of 
a LMNA mutation (52). Upholding the structure of the nucleus, 
chromatin arrangement, and gene expression is encoded by the 
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LMNA gene for the A-type lamins (53). In a study by Roncarati 
et al., the presence of the TTN variant and the LMNA mutation 
carriers modified DCM patients’ clinical course and disease 
severity, with double heterozygotes requiring earlier heart trans-
plantation (four individuals) compared with those only harbor-
ing the LMNA mutation alone. Furthermore, histological studies 
showed more evidence that double heterozygote individuals had 
worse outcomes on a cellular level (48). In conclusion, this study 
suggests a modifier role of TTN variants that contribute to the 
complexity of the DCM phenotype.
CLiNiCAL ASSeSSMeNT 
OF TiTiN vARiANTS
Titin has been known to be cause a DCM phenotype for many 
years; however, the systematic analysis and the complete mean-
ing of its contribution to DCM have been precluded by its giant 
size and sequencing technical limitations (54). As discussed 
earlier, using NGS, Herman et  al. found that heterozygous 
mutations truncating the full-length TTN are the most com-
mon causes of DCM; occurring in ~25% of familial cases of 
DCM and 18% of sporadic cases. However, TTN truncating 
variants were also found in ~2% of healthy controls (16, 55), 
raising concern about the correct clinical interpretations of 
TTN variants. The finding of a TTN truncating variant in a 
patient before the onset of clinical manifestation of disease 
thus requires further in-depth analysis to support pathogenicity 
(9). Additional factors, such as band location and PSI score, 
might help to differentiate pathogenic truncation mutations 
from benign variants (28, 36). This is of particular importance 
considering that most DCM patients present late in the course 
of the disease (advanced disease presenting with heart failure 
or sudden cardiac death), while the early detection of asymp-
tomatic DCM might be critical to enable early intervention 
that may prevent the progression to advanced disease (56). 
Moreover, TTN truncation variants may be found in association 
with other disease-related genes, increasing the concerns about 
the actual role of some TTN mutations (37).
Analysis of a large number of genes has led to the identification 
of sequence VUS. These VUS are one of the main challenges of 
NGS, because cardiologists and clinical geneticists are faced with 
uncertainty of the clinical meaning of VUS findings (57).
To date indeed, a large number of identified TTN truncating 
variants are still classified as VUS, and the high prevalence of 
missense variants in TTN, and their potential modifier roles 
make interpretation difficult in both research and the clinical 
settings. The location of TTN truncating variants can contribute 
to a better definition of genetic findings, because as already 
mentioned, TTN truncating variants associated with DCM are 
located predominantly in the A-band (16, 38). The availability 
of multiple family members to test for cosegregation with 
disease, the absence in population databases (ClinVar, ExAC, 
1000 Genomes Project, and NHLBI Exome Sequencing Project), 
prediction software (PolyPhen, SIFT, GERP), and functional data 
also add in the understanding of classifying the pathogenicity of 
TTN variants (9). Most importantly, NGS has to be considered 
a diagnostic test in development and testing results need to be 
interpreted cautiously in close collaboration between bioformati-
cians, cardiologists, molecular biologists, and clinical geneticists 
preferably in expert centers. Many novel variants identified by 
NGS and classified as VUS present as an inconclusive test result, 
pending further evidence (57).
Once the pathogenic effect has been defined, another concern 
is the variability in phenotype expression based on the presence 
and type of TTN mutation variants. Roberts et  al. found more 
severe impaired LV function, lower stroke volume, and thinner 
LV walls in TTN truncating than in TTN truncating negative 
DCM patients (Figure 4) (28). In this cohort, the TTN genotype 
independently predicted phenotype severity. Furthermore, TTN 
truncating positive patients more frequently suffer from sustained 
ventricular tachycardia (28). In the future, if larger prospective 
studies confirm these findings, TTN mutations might influence 
the decision-making process for the selection of candidates to 
an implantable cardioverter defibrillator (ICD) implantation, 
such as in other cardiomyopathies at high risk of life-threatening 
arrhythmias (58).
Mutations in TTN and other proteins affecting TTN splicing 
are associated with the development of DCM, but these mecha-
nisms are still not completely understood (59). Variable isoform 
expression and TTN splicing have become of great importance 
in DCM, and are associated with decreasing passive stiffness and 
increasing chamber compliance (26). Both mechanisms might be 
important in the process of DCM in connection to TTN muta-
tions. By genetic approaches or by splicing or posttranslational 
modifications TTN appears to be a target for future therapeutic 
interventions (9).
Regarding the universe of TTN missense variants, the situ-
ation is even more challenging because TTN missense variants 
are very common and their real meaning is still unknown. 
A recent study demonstrated that missense variants did not 
correlate with the clinical measures of disease severity or 
progression and indicated that the DCM phenotype caused 
by TTN missense variants are not distinguishable from other 
types of DCM (Figure  3). According to the authors, TTN 
rare missense mutations should not be currently interpreted 
as disease-causing in most situations (38). Nevertheless, there 
is some interesting evidence that TTN missense mutations may 
have a modifier role leading to a greater severity of cardio-
myopathy (17, 48). In the future, a better understanding of 
the TTN missense variants in DCM will be elucidated with 
large-scale TTN sequencing and functional investigations on 
TTN variant domains.
Finally, despite the recent advances in genetic studies and in the 
understanding of the different effects of specific gene mutations 
in the pathogenesis of DCM, the clinical approach to diagnosing 
cardiomyopathy affected families remains largely based on the 
general recommendations for heart failure management, familiar 
screening programs, and systematic follow-up. The continuous 
improvement in technologies, such as the increasing evidence 
concerning the clinical expression of different gene variants 
might lead in the future to an individualized clinical approach to 
identifying carriers of different mutations.
FiGURe 4 | Survival of TTN truncation carriers. Patients carriers of a TTN truncation variant (TTNtv) had a worse clinical outcome when considering the age of 
adverse event (death, cardiac transplant or left ventricular assisted device) (P = 0.015). They also had a worse clinical outcome when considering the time of event 
from enrollment (from Roberts et al., with permission) (28).
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CONCLUSiON
Titin is the largest protein in striated muscle. TTN variants 
have been shown to cause the following cardiac diseases: 
DCM, RCM, HCM, and ARVC. The advancement of NGS has 
allowed researchers to analyze the whole TTN gene, which has 
revealed the leading role of this gene in DCM. Challenges are 
the high genetic variability of the gene, the large number of 
missense and truncation variants found in control populations, 
and the criteria for clinical diagnosis of many variants demand 
individualized clinical diagnosis platforms for TTN carriers. 
Future studies will clarify whether the early identification of 
TTN-related cardiomyopathies might positively influence the 
natural history of disease by the early initiation of therapeutic 
management.
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